{"reformulated1": "What are the latest advances in cleavable linker technologies for antibody-drug conjugates, including stimuli-responsive and traceless linker designs?", "reformulated2": "How do site-specific conjugation strategies, such as engineered cysteines and enzymatic methods, improve the homogeneity and stability of ADC linker attachment?", "reformulated3": "What polymer-modified and multiloading linker approaches have been developed to enhance the pharmacokinetic properties and drug-to-antibody ratios in modern ADCs?"}
